Curated Information
Javascript is not enabled on this browser. This site will not work properly without Javascript.
PhosphoSitePlus Homepage Cell Signaling Technology
PhosphoSitePlus
HomeAbout PhosphoSiteUsing PhosphoSiteCuration ProcessContact
NIH-logos NIGMS Logo NIAAA Logo NCI Logo NIH Logo
Curated Information Page
PubMed Id: 18847491 
This page summarizes selected information from the article referenced above and curated into PhosphoSitePlus®, a comprehensive online resource for the study of protein post-translational modifications (NAR, 2012,40:D261-70). To learn more about the scope of PhosphoSitePlus®, click here.
Information from this record has been curated, but not yet edited in PhosphoSitePlus® and may be incomplete.
Shi Y, Sahu RP, Srivastava SK (2008) Triphala inhibits both in vitro and in vivo xenograft growth of pancreatic tumor cells by inducing apoptosis. BMC Cancer 8, 294 18847491
Only sites from this record are displayed on this page. Click on the protein name to open the protein page, and on the RSD number to open the site page. For the complete dataset, click the download button, on the right.
Download Sites

S1981-p - ATM (human) ▲
Orthologous residues
ATM (human): S1981‑p, ATM (mouse): S1987‑p
Characterization
 Methods used to characterize site in vivo:  phospho-antibody, western blotting
 Disease tissue studied:  pancreatic cancer, pancreatic carcinoma
 Relevant cell lines - cell types - tissues:  BxPC-3 (pancreatic), Capan1 (pancreatic)
 Cellular systems studied:  cell lines
 Species studied:  human
Upstream Regulation
 Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
increase Triphala

T202-p - ERK1 (human) ▲
Orthologous residues
ERK1 (human): T202‑p, ERK1 (mouse): T203‑p, ERK1 (rat): T203‑p, ERK1 (hamster): T192‑p
Characterization
 Methods used to characterize site in vivo:  phospho-antibody, western blotting
 Disease tissue studied:  pancreatic cancer, pancreatic carcinoma
 Relevant cell lines - cell types - tissues:  BxPC-3 (pancreatic), Capan1 (pancreatic)
 Cellular systems studied:  cell lines
 Species studied:  human
Upstream Regulation
 Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
increase TPL
N-acetylcysteine inhibit treatment-induced increase
U0126 inhibit treatment-induced increase BxPC3 cells
no change compared to control TPL, HPDE-6 cells
increase TPL, xenograph tumor lysates

Y204-p - ERK1 (human) ▲
Orthologous residues
ERK1 (human): Y204‑p, ERK1 (mouse): Y205‑p, ERK1 (rat): Y205‑p, ERK1 (hamster): Y194‑p
Characterization
 Methods used to characterize site in vivo:  phospho-antibody, western blotting
 Disease tissue studied:  pancreatic cancer, pancreatic carcinoma
 Relevant cell lines - cell types - tissues:  BxPC-3 (pancreatic), Capan1 (pancreatic)
 Cellular systems studied:  cell lines
 Species studied:  human
Upstream Regulation
 Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
increase TPL
N-acetylcysteine inhibit treatment-induced increase
U0126 inhibit treatment-induced increase BxPC3 cells
no change compared to control TPL, HPDE-6 cells
increase TPL, xenograph tumor lysates

T185-p - ERK2 (human) ▲
Orthologous residues
ERK2 (human): T185‑p, ERK2 (mouse): T183‑p, ERK2 (rat): T183‑p, ERK2 (chicken): T193‑p
Characterization
 Methods used to characterize site in vivo:  phospho-antibody, western blotting
 Disease tissue studied:  pancreatic cancer, pancreatic carcinoma
 Relevant cell lines - cell types - tissues:  BxPC-3 (pancreatic), Capan1 (pancreatic)
 Cellular systems studied:  cell lines
 Species studied:  human
Upstream Regulation
 Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
increase TPL
N-acetylcysteine inhibit treatment-induced increase
U0126 inhibit treatment-induced increase BxPC3 cells
no change compared to control TPL, HPDE-6 cells
increase TPL, xenograph tumor lysates

Y187-p - ERK2 (human) ▲
Orthologous residues
ERK2 (human): Y187‑p, ERK2 (mouse): Y185‑p, ERK2 (rat): Y185‑p, ERK2 (chicken): Y195‑p
Characterization
 Methods used to characterize site in vivo:  phospho-antibody, western blotting
 Disease tissue studied:  pancreatic cancer, pancreatic carcinoma
 Relevant cell lines - cell types - tissues:  BxPC-3 (pancreatic), Capan1 (pancreatic)
 Cellular systems studied:  cell lines
 Species studied:  human
Upstream Regulation
 Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
increase TPL
N-acetylcysteine inhibit treatment-induced increase
U0126 inhibit treatment-induced increase BxPC3 cells
no change compared to control TPL, HPDE-6 cells
increase TPL, xenograph tumor lysates

S140-p - H2AX (human) ▲
Orthologous residues
H2AX (human): S140‑p, H2AX (mouse): S140‑p, H2AX (rat): S140‑p
Characterization
 Methods used to characterize site in vivo:  phospho-antibody, western blotting
 Disease tissue studied:  pancreatic cancer, pancreatic carcinoma
 Relevant cell lines - cell types - tissues:  BxPC-3 (pancreatic), Capan1 (pancreatic)
 Cellular systems studied:  cell lines
 Species studied:  human
Upstream Regulation
 Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
increase Triphala

S218-p - MEK1 (human) ▲
Orthologous residues
MEK1 (human): S218‑p, MEK1 (mouse): S218‑p, MEK1 (rat): S218‑p, MEK1 (rabbit): S218‑p
Upstream Regulation
 Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
increase Triphala
increase Triphala

S15-p - p53 (human) ▲
Orthologous residues
p53 (human): S15‑p, p53 (mouse): S15‑p, p53 iso2 (mouse): S18‑p, p53 (rat): S15‑p, p53 (rabbit): S15‑p, p53 (monkey): S15‑p
Characterization
 Methods used to characterize site in vivo:  phospho-antibody, western blotting
 Disease tissue studied:  pancreatic cancer, pancreatic carcinoma
 Relevant cell lines - cell types - tissues:  BxPC-3 (pancreatic), Capan1 (pancreatic)
 Cellular systems studied:  cell lines
 Species studied:  human
Upstream Regulation
 Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
increase Triphala
increase Triphala (TPL)
pifithrin-alpha inhibit treatment-induced increase
U0126 inhibit treatment-induced increase
N-acetylcysteine inhibit treatment-induced increase
no change compared to control TPL, HPDE-6 cells
decrease TPL, xenograph tumor lysates


Home  |  Curator Login With enhanced literature mining using Linguamatics I2E I2E Logo Produced by 3rd Millennium  |  Design by Digizyme
©2003-2013 Cell Signaling Technology, Inc.